www.innocarepharma.com Open in urlscan Pro
65.52.168.70  Public Scan

Form analysis
1 forms found in the DOM

/en/search-result/

<form class="form-search form-inline" action="/en/search-result/">
  <div class="form-group">
    <input type="text" id="search" name="query" placeholder="Search">
    <div id="form-button">
      <span class="glyphicon glyphicon-search search-icon"></span>
      <svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" class="glyphicon close-icon" width="18px" height="18px" viewBox="0 0 30 30" version="1.1">
        <g id="surface1">
          <path style=" stroke:none;fill-rule:nonzero;fill-opacity:1;"
            d="M 29.699219 2.878906 L 27.121094 0.300781 L 15 12.421875 L 2.875 0.300781 L 0.300781 2.878906 L 12.421875 15 L 0.300781 27.121094 L 2.875 29.699219 L 15 17.578125 L 27.121094 29.699219 L 29.699219 27.121094 L 17.578125 15 Z M 29.699219 2.878906 ">
          </path>
        </g>
      </svg>
    </div>
  </div>
</form>

Text Content

EN | 简 | 繁


 * About Us
   * Our Story
   * Our Team
   * Leadership Message
   * Dedicated and Deliver
   * Contact Us
 * Pipeline
   * Our Science
   * Our Pipeline
   * Expanded Access Policy
 * Business Development
 * Investor Relations
   * Corporate Information
   * Listing Documents
   * Stock Information
   * Financial Reports
   * ESG Reports
   * Corporate Governance
   * Investor Presentation
   * Announcements
   * Event Calendar
   * Subscription Centre
   * IR Contact
 * Careers
   * Job Opportunities
   * Campus Recruitment
 * Media
   * Press Release

 * 
 * 
 * 

We are a leading biopharmaceutical company with a fully-integrated research to
commercialization platform.
Who we are?

We are committed to discovering, developing and commercializing best-in-class
and/or first-in-class drugs for the treatment of cancer and autoimmune diseases.
Led by a world-class management team of seasoned industry executives, we have
built a fully integrated biopharmaceutical platform with strong in-house R&D
capabilities, including drug target identification and verification, preclinical
evaluation, clinical trial design and execution, drug manufacturing and quality
control, and commercialization.

Read More
Our Pipeline

We focus on the discovery and development of innovative medicines to address
significant unmet medical needs of diseases that are specially prevalence in
Chinese population.

Autoimmune Diseases
Oncology Therapeutic
Read More
InnoCare is devoted to providing the best products to the market.
Dedicated and Deliver

We have built a fully integrated biopharmaceutical platform that allows us to
oversee all aspects of the drug development cycle. By having all functions
in-house, we are able to improve operational efficiency and control quality
every step of the way.

Read More

Company News
13/09/2022

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in China

Read More
09/09/2022

InnoCare Announces First Patient Dosed in Phase II Registrational Trial of
Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse
Large B-Cell Lymphoma in China

Read More
06/09/2022

InnoCare Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL
by NMPA

Read More
Investor Relations
Share Graph
Company Announcement
IR Contact
© 2016 InnoCare. All Rights Reserved.
京ICP备16037514号-5|
京公网安备11011402010425号
 * About Us
   * Our Story
   * Our Team
   * Leadership Message
   * Dedicated and Deliver
   * Contact Us
 * Pipeline
   * Our Science
   * Our Pipeline
   * Expanded Access Policy
 * Business Development
 * Investor Relations
   * Corporate Information
   * Listing Documents
   * Stock Information
   * Financial Reports
   * ESG Reports
   * Corporate Governance
   * Investor Presentation
   * Announcements
   * Event Calendar
   * Subscription Centre
   * IR Contact
 * Careers
   * Job Opportunities
   * Campus Recruitment
 * Media
   * Press Release

 * About Us
   
 * Pipeline
   
 * Business Development
   
 * Investor Relations
   
 * Careers
   
 * Media
   


 * 
 * 
 * 
 * 
 * 
 * 
 *